Evaluating surgical outcomes for testicular cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the oncologic and functional outcomes of retroperitoneal lymph node dissection (RPLND) in patients with testicular cancer, focusing on both primary treatment and treatment of residual masses after chemotherapy. It includes a multicenter prospective observational phase where patients undergo RPLND using open, laparoscopic, or robot-assisted techniques, as well as a retrospective phase analyzing data from patients treated between 2000 and 2020. The study will follow patients for five years to evaluate the effectiveness of these surgical approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged ≥ 18 years
* RPLND of residual mass after chemotherapy in patient with testicular neoplasm seminomatous or nonseminomatous performed by open, laparoscopic, or robotic technique
* Primary RPLND for seminomatous or nonseminomatous testicular neoplasm of stage I or IIA-IIB with negative markers performed with open, laparoscopic or robotic technique
* RPLND performed by open, laparoscopic, or robotic technique for the treatment of tumors seminomatous or nonseminomatous chemiorefractory testicular tumors progressing after I and II line of chemotherapy
* Acquisition of informed consent

Exclusion criteria:

* Patient with comorbidities with contraindication to surgery
* Hemorrhagic diathesis

RETROSPECTIVE PHASE. Patients with the same inclusion and exclusion criteria as in the prospective phase and already undergoing RPLND surgery with open, laparoscopic, or robotic technique from January 2000 to December 2020 in the͛framework of the normal course of care with a minimum follow-up of 12 months. (estimated to include approximately 120 patients).

Where it's running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna
  Bologna, Bologna, Italy Recruiting
• UO di Chirurgia Urologica della Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
  Milan, Italy, Italy Recruiting

Study contacts

• Principal investigator: Eugenio Brunocilla, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Angelo Mottaran, MD
• Email: angelo.mottaran2@unibo.it
• Phone: +39 3398946529

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Primary retroperitoneal lymph node surgery versus chemotherapy for good‑prognosis metastatic testicular cancer

  This study will test whether primary RPLND (surgery) instead of standard chemotherapy leads to fewer side effects and better quality of life for men 18 and older with good‑prognosis metastatic testicular cancer.

  Recruiting Sahlgrenska University Hospital · Gothenburg, Göteborg · NCT07498959

• Sodium thiosulfate to protect hearing during cisplatin therapy in adults with solid tumors

  This study tests Pedmark sodium thiosulfate to see if it reduces hearing loss in adults receiving standard cisplatin chemotherapy.

  Recruiting Phase 1/2 University of Arizona · Tucson, Arizona · NCT07407582

• Navigation program for young cancer survivors

  This project tests an adapted navigation program to help adolescent and young adult cancer survivors get timely care within Kaiser Permanente Southern California.

  Recruiting Kaiser Permanente · Pasadena, California · NCT07406087

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Testing GV20-0251 for advanced or treatment‑resistant solid tumors

  This study will test whether GV20-0251 is safe and tolerable when given every three weeks to adults with advanced or treatment‑resistant solid tumors such as liver, lung, pancreatic cancer, and melanoma.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07106827

• How retroperitoneal lymph node dissection affects urination and sexual function

  This project will see if retroperitoneal lymph node dissection (RPLND) for testicular cancer changes urination, ejaculation, erections, and quality of life in adult men.

  Recruiting Jagiellonian University · Krakow, Malopolska · NCT06954233

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.